Fosun Pharmaceutical Unit Gets China Nod for Lung Cancer Drug Trial

MT Newswires Live

Yesterday

A unit of Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit obtained approval from China's National Medical Products Administration for the clinical trial of Foritinib Succinate Capsules, a Monday Hong Kong bourse filing said.

The trial will study the drug for adjuvant treatment following the radical resection of tumor in patients with stage IB to IIIA non-small cell lung cancer.

Unit Fosun Wanbang (Jiangsu) Pharmaceutical Group will begin the phase III trial of the drug once the relevant conditions are met.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2565689357"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565689357\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565689357?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565689357","market":"sg","top_or_hot":-1,"title":"Fosun Pharmaceutical Unit Gets China Nod for Lung Cancer Drug Trial","media":"MT Newswires Live","content":"<html><body><p> A unit of <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (SHA:600196, HKG:2196) unit obtained approval from China's National Medical Products Administration for the clinical trial of Foritinib Succinate Capsules, a Monday Hong Kong bourse filing said.</p><p>The trial will study the drug for adjuvant treatment following the radical resection of tumor in patients with stage IB to IIIA non-small cell lung cancer.</p><p>Unit Fosun Wanbang (Jiangsu) Pharmaceutical Group will begin the phase III trial of the drug once the relevant conditions are met.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharmaceutical Unit Gets China Nod for Lung Cancer Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharmaceutical Unit Gets China Nod for Lung Cancer Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-08 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> A unit of <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (SHA:600196, HKG:2196) unit obtained approval from China's National Medical Products Administration for the clinical trial of Foritinib Succinate Capsules, a Monday Hong Kong bourse filing said.</p><p>The trial will study the drug for adjuvant treatment following the radical resection of tumor in patients with stage IB to IIIA non-small cell lung cancer.</p><p>Unit Fosun Wanbang (Jiangsu) Pharmaceutical Group will begin the phase III trial of the drug once the relevant conditions are met.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2565689357","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565689357","pubTimestamp":1757332735,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"A unit of Shanghai Fosun Pharmaceutical  unit obtained approval from China's National Medical Products Administration for the clinical trial of Foritinib Succinate Capsules, a Monday Hong Kong bourse filing said.The trial will study the drug for adjuvant treatment following the radical resection of tumor in patients with stage IB to IIIA non-small cell lung cancer.Unit Fosun Wanbang  Pharmaceutical Group will begin the phase III trial of the drug once the relevant conditions are met.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0012":"证金概念","02196":"复星医药","00656":"复星国际","BK0028":"国家队","BK0239":"医药制造","BK0060":"抗癌","BK0183":"MSCI概念","BK0187":"一线龙头","BK0096":"民营医院","BK1515":"抗疫概念","BK1191":"制药","BK0188":"融资融券","BK1593":"医美概念股","BK0175":"白马股","BK0196":"行业龙头"},"translate_title":"复星医药子公司肺癌药物试验获得中国认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":1,"02196":0.9},"content_text":"A unit of Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit obtained approval from China's National Medical Products Administration for the clinical trial of Foritinib Succinate Capsules, a Monday Hong Kong bourse filing said.The trial will study the drug for adjuvant treatment following the radical resection of tumor in patients with stage IB to IIIA non-small cell lung cancer.Unit Fosun Wanbang (Jiangsu) Pharmaceutical Group will begin the phase III trial of the drug once the relevant conditions are met.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}